With US FDA action on teprotumumab anticipated in March, Horizon has assembled a 100-person commercial team to begin educating physicians and payers on the rare autoimmune condition thyroid eye disease (TED).

HRSA proposes another delay to effective date of final rule on calculating the ceiling prices for drugs sold to 340B program. Agency also appears ready to reconsider the 'penny pricing' policy that rule would codify.

Otsuka's purchase of Neurovance is part of a larger strategy to replace revenues lost to patent expiration of Abilify. Meanwhile, its Japanese counterpart Takeda is overhauling its R&D engine with help from contract manufacturer Bushu.

Horizon will boost its orphan drug business through the acquisition of Raptor, using a combination of debt and cash from its primary care and other assets to fund the transaction.